Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB107-RRV and DB107-FC in Recurrent Glioblastoma or Anaplastic Astrocytoma
NCT06264388Phase 2Recruiting
- Sponsor
- Ashish Life Science
- Start
- May 2024
- Primary completion
- May 2034
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of vocimagene amiretrorepvec in glioma, anaplastic astrocytoma (AA), glioblastoma (GBM), sponsored by Ashish Life Science. Started May 2024; status: recruiting.
02
Drugs
vocimagene amiretrorepvec
03
Conditions
gliomaanaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06264388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264388.